Home
Latest
E-paper
Companies
Industry
Economy
Blueprint
Finance
Markets
Budget
India News
Politics
External Affairs Defence Security
World News
Opinion
Technology
Immigration
Specials
Partner Content
Sports
Cricket
Lifestyle
Entertainment
Social Viral
Health
BS Decoded
Books
Education
Newsletters
Web Stories
BS at 50
Multimedia
Sudoku
Crossword
BS Apps
Management
Indulgence
Premium
Explore Business Standard
BFSI Insight Summit
Events
About Us
BS Support
Popular Search
Margin improvement holds key for Lupin with US sales likely to soften
Go ahead for inhaler launch in the US and resolution of plant compliance issues are other triggers
Lupin reports 25% fall in pre-tax profit at Rs 412 cr in Q4 on low sales
On a sequential basis, however, the company fared better, both in terms of sales and profits. The stock ended day's trade at Rs 869.8, down 1.3 per cent.
Lupin Q3 net loss widens to Rs 835 crore, sales drop to Rs 3,716 crore
Consolidated sales of the company stood at Rs 3,716 crore for the quarter under consideration
Lupin posts Q3 loss of Rs 152 crore on litigation over blood pressure drug
Lupin reported a one-time charge of Rs 342 crore in Q3
Lupin fourth quarter profit up 48%, beats estimates
Company reported a net profit of Rs 807 crores for the January-March quarter